<DOC>
	<DOC>NCT02609659</DOC>
	<brief_summary>This study seeks to assess the safety and efficacy of treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in non-cirrhotic, genotype 1a (GT1a) hepatitis C virus infected participants who are treatment-naïve or treatment-experienced with Interferon (IFN) or Pegylated Interferon (pegIFN) with or without Ribavirin (RBV).</brief_summary>
	<brief_title>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Chronic HCV infection Noncirrhotic subjects Screening laboratory results showing HCV Genotype 1a infection HCV treatmentnaïve or if treated previously, only with IFN or pegINF with or without RBV Pregnant or breastfeeding women Positive for hepatitis B surface antigen (HBsAg) or antihuman immunodeficiency virus antibody (HIV Ab) HCV genotype of any subtype other than 1a or unable to subtype Prior or current use of any investigational or commercially available antiHCV agents other than IFN, pegIFN or RBV. Subjects with previous participation in trials of investigational directacting antiviral agents (DAAs) may be enrolled if they can produce documentation that they received only placebo. Current enrollment in another interventional clinical study or receipt of any investigational product within 6 weeks prior to study drug administration.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic Hepatitis C Infection</keyword>
</DOC>